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Introduction
Borrowing from Juvenal, Nassim Nicholas Taleb 
developed his “Black Swan” theory as an unexpected 
and abnormal event of great importance, capable 
of generating significant environmental changes 
whose meaning, although implicit, is grasped only a 
posteriori [1].
Politicians and commentators, scientists even, regarded 
the COVID-19 pandemic as a Black Swan event; 
actually, we should wonder whether the black swan 
could be not the pandemic rather than its epidemiological 
management.
Laboratory test results drove most decisions to manage 
the pandemics spread; however, their use is often clumsy 
and inappropriate and deserves to be discussed.
Laboratory tests are useful in distinguishing positive 
from negative, i.e., sick from healthy. This characteristic 
is relevant during an epidemic event because it allows 
the adaptation of both therapeutic and health policy 
choices to contain the disease’s spread. 
The characteristics that allow bettering separate the 
healthy population from the affected one must be 
verified for the latter use. Negative predictive values 
(NPV) and false omission rate (FOR) are the parameters 
that need consideration. NPV is a test capability to be 
negative in non-affected people[NPV  =  (1-prevalence) 
specificity  /  (1-prevalence) specificity  +  prevalence 
(1-sensitivity)]. FOR is the complementary quantification 
of false-negatives (FN). 
In the early pandemic stages, the lack of knowledge 
of various diagnostic tests’ analytical performances 
was a weak point for infection containment measures’ 
effectiveness. 
Later, most serological qualitative tests seemed 
inadequate in detecting anti-COVID19 antibodies. 
The window-phase bounding and IgM timing to IgG 
seroconversion proved to be the most criticalities [2-4].
In Italy, serological tests’ unreasonable use has 
caused considerable uncertainty, which has proved 
relevant for the maintenance or readmission to health 
personnel’s work. These measures include a two-step 
protocol –  IgM/IgG anti-COVID followed by RT-PCR 
in the serologically positive only  –  to identify health 
workers who could continue to be operational or, 
conversely, to be quarantined [5].
This protocol could be affected by severe uncertainties 
arising from the analytical limitations of the tests used. 
Methods
We evaluated serological tests’ analytical specifications 
under different prevalence conditions to quantify this 
defect. 
By way of example the serological tests considered 
are:  1)  COVID-19 IgG/IgM (Screen Italia, Perugia, 
Italy); 2)  Liaison SARS-CoV-2 S1/S2 IgG (Diasorin, 
Saluggia, Italy); 3)  Maglumi 2019-nCoV IgG; and 
4)  Maglumi 2019-nCoV IgM+IgG (Snibe Diagnostic, 
Shenzhen, China).
“Black Swan” is an unexpected and catastrophic event character-
ized by three conditions: the anomalous and exceptional value, 
the extreme impact, and predictability a posteriori. On many 
sides – by politicians, commentators, scientists – there have been 
attempts to give the COVID-19 pandemic event the meaning of 
Black Swan. In reality, one should wonder if the Black Swan 
was not, instead (or even), the way the epidemic was handled. 
In Italy, an unreasonable use of a two-step protocol - IgM/IgG 
anti-COVID followed by RT-PCR in the serologically positive 
only has caused considerable uncertainty, particularly relevant 
in measures for maintenance or readmission to work of health 
personnel. This protocol could be affected by serious uncertain-
ties arising from the analytical limitations of the tests used. To 
quantify this defect, we evaluated the analytical specifications of 
serological tests under different prevalence conditions. In conclu-
sion, although laboratory diagnostics represent a useful tool, it 
can only be used for epidemiological purposes and not to provide 
healthy pass.
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Concerning the direct research of the COVID-19 
virus with RT-PCR method, we referred to the 
performances reported for different technologies and [6] 
on nasopharyngeal swabs (NP) and bronchoalveolar 
washes (BAL), for which sensitivity of 63% and 93% 
respectively were reported [7].
The exact prevalence of COVID-19 infection is affected 
by various factors such as regional variability  [8] and 
an unspecified number of non-swab-tested healthy 
carriers  [9,  10]. We calculated each serological test 
for FN rate related to their NPV and FOR in different 
prevalence values. Since FN rate rises as prevalence 
increases, the resulting number might consider an 
estimate of health care providers admitted to caring 
services, despite their infectivity.
Results
As shown in Table I, depending on the NPV and FOR 
showed by the used test, FNs subjects range between 
11 and 134, in a population of 1,000  inhabitants with 
infection prevalence equal to 0.3 (300 positives). 
Unfortunately, in the second phase of viral research 
on serologically positive subjects, further FNs will 
be are added. For example, in the same population 
prevalence, an RT-PCR method with a sensitivity of 0.7 
will demonstrate VNP and FOR values that will result in 
16 FN out of a total of 166 VP [11]. 
The result of two-step screening is that 152  positive 
subjects out of 300 could be classified incorrectly as 
negative. This result comes from 134  IgM/IgG FNs 
with 18  FNs resulting from RT-PCR under the given 
conditions. Fewer FNs are achieved using other 
methodologies and/or different prevalence values; 
however, the best result of 43  FN remains equally 
worrying because of the obvious fallout on the possible 
expansion of contagion.
Discussion 
Two step protocol could be affected by serious 
uncertainties arising from the analytical specifications 
of the tests under different prevalence conditions.
Our analysis shows that performing RT-PCR research 
exclusively on positive IgM/IgG subject prevents the 
discovery of numerous infected operators due to the 
combined methodological error of used tests in the two 
steps. 
The risk of two-stage screening is that a critical number 
of positive subjects may be wrongly classified as 
negative. This risk become more relevant the higher the 
amount of prevalence of those affected.
Therefore, the consequent unknown presence of false 
negatives can be a danger and source of outbreaks.
Conclusions
Unreasonable use of serological tests may have caused 
considerable uncertainty, particularly relevant in 
maintenance or readmission to work of health personnel, 
using a two-step protocol  -  IgM/IgG anti-COVID 
followed by RT-PCR in the serologically positive only.
The non-segregation of these subjects and their free 
working activity in the healthcare environment represents 
an insidious source of new disease outbreaks, making 
containment null. 
This appraisal could be evoked to explain the high 
incidence of infections (and deaths) among operators 
and patients in some Italian regions with the highest 
prevalence, such as Lombardia and Emilia Romagna.
These pieces of evidence could have suggested the 
combined use (instead of sequential) of both serology 
and RT-PCR [12]. Such choice would have enhanced the 
ability to intercept affected subjects and perhaps have 
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Pre NPV FOR FN NPV FOR FN NPV FOR FN NPV FOR FN NPV FOR FN 
0.10 0.994 0.006 6 0.961 0.039 39 0.997 0.003 3 0.990 0.010 10 0.995 0.005 5
0.20 0.987 0.013 13 0.917 0.083 83 0.993 0.007 7 0.978 0.022 22 0.989 0.011 11
0.30 0.979 0.021 21 0.866 0.134 134 0.989 0.011 11 0.963 0.037 37 0.982 0.018 18
0.40 0.967 0.033 33 0.806 0.194 194 0.983 0.017 17 0.943 0.057 57 0.972 0.028 28
0.50 0.951 0.049 49 0.735 0.265 265 0.974 0.026 26 0.917 0.083 83 0.958 0.042 42
0.60 0.929 0.071 71 0.649 0.351 351 0.962 0.038 38 0.881 0.119 119 0.938 0.062 62
0.70 0.894 0.106 106 0.543 0.457 457 0.942 0.058 58 0.826 0.174 174 0.907 0.093 93
0.80 0.831 0.169 169 0.409 0.591 591 0.904 0.096 96 0.735 0.265 265 0.851 0.149 149
0.90 0.685 0.315 315 0.235 0.765 765 0.808 0.192 192 0.552 0.448 448 0.717 0.283 283
Pre: prevalence; Se: sensitivity; Sp: pecificity; NPV: negative predictive value; FOR: false omission rate; FN: false negative per thousand. Screen rest Se 
and Sp are relative – RT-PCR reference gold standard. Real Se and Sp are obtained by considering RT-PCR Broncho Alveolar Lavage (BAL) and RT-PCR na-
sopharyngeal (NF) as gold standard.
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averted the Black Swan spread of Covid-19, increasing 
safety levels.
In conclusion, Laboratory tests can help to distinguish 
positive from negative, i.e., sick from healthy; but it 
depends on their characteristics. Although both serological 
tests and RT-PCR are useful tools, they can only be used for 
epidemiological purposes and not to provide healthy pass.
At present, the correct behavior would be to consider all 
subjects present in hospitals as potentially infected, in 
order to enhance security. 
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